Targeting lung cancer cells with a new small-molecule treatment
Targeting non-small cell lung cancer cells and the adverse tumor microenvironment with a small-molecule STAT3 inhibitor
This study is testing a new treatment called TTI-101 for people with advanced non-small cell lung cancer, aiming to see if it can help improve their outcomes by blocking a protein that makes the cancer worse.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | University of Tx Md Anderson Can Ctr NIH-funded |
| Lab location | 1 site (Houston, United States) |
| Project ID | NIH-11002302 on NIH RePORTER |
What this research studies
This research focuses on developing a new treatment for non-small cell lung cancer (NSCLC) by using a small-molecule inhibitor called TTI-101 that targets a protein known as STAT3. Elevated levels of STAT3 are linked to poor outcomes in NSCLC, and this study aims to block its activity to improve treatment responses. The approach involves both laboratory studies and clinical trials to assess the safety and effectiveness of TTI-101 in patients with advanced lung cancer. Patients may be monitored for tumor growth and any adverse effects during the treatment process.
Who could benefit from this research
Good fit: Ideal candidates for this research are patients diagnosed with advanced or refractory non-small cell lung cancer who have not responded well to existing therapies.
Not a fit: Patients with early-stage lung cancer or those whose cancer is not classified as non-small cell lung cancer may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to a more effective treatment option for patients with non-small cell lung cancer, potentially improving survival rates.
How similar studies have performed: Previous studies have shown promise with similar approaches targeting STAT3 in cancer treatment, indicating potential for success in this novel application.
Where this research is happening
Houston, United States
- University of Tx Md Anderson Can Ctr — Houston, United States (Active)
Researchers
- Principal investigator: Tweardy, David John — University of Tx Md Anderson Can Ctr
- Study coordinator: Tweardy, David John
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.